Filter Results:
(3,422)
Show Results For
- All HBS Web
(3,422)
- People (9)
- News (721)
- Research (2,192)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,298)
Show Results For
- All HBS Web
(3,422)
- People (9)
- News (721)
- Research (2,192)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,298)
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry
Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details
- 15 Sep 2003
- Research & Ideas
The Lessons of New-Market Disruption
Teradyne: Testing Opportunity In 1994, Teradyne, a leading provider of machines that test the quality of microprocessors and other integrated circuits as they come off the assembly line, saw an opportunity... View Details
- Web
Admissions Resources - Doctoral
letters, and suggestions on how to identify and approach your recommenders. Standardized Tests As you prepare for your PhD application, watch this video to learn more about what standardized tests are... View Details
- October 2013
- Case
FasterCures: Removing Barriers to Treatments
By: Richard G. Hamermesh and James Weber
In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details
Keywords: Health Care; Health Care Industry; Health Care Policy; Health Services; Healthcare; Healthcare Reform; Healthcare Ventures; Nonprofit; Non-profit Management; Not-for-profit; Incubator; Accelerator; Venture Philanthropy; Medical Services; Medical Solutions; Medical Research; Medical Treatment; Clinical Trials; Drug Reimbursement; Early Stage; Early Stage Research Funding; Early Stage Funding; Milken Institute; Michael Milken; David Baltimore; Partnering For Cures; National Institutes Of Health; Cancer Care In The U.S.; Cancer Care Services; Policy-making; Health Care and Treatment; Health; Health Testing and Trials; Entrepreneurship; Social Entrepreneurship; Nonprofit Organizations; Policy; Health Industry; United States; District of Columbia
Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.
- 23 Jul 2008
- Sharpening Your Skills
Sharpening Your Skills: Balanced Scorecard in Action
reduce the gap between strategy and execution? Does the BSC work in testing strategy? How Can The Balanced Scorecard Improve Corporate Governance? Working Paper: Improving Corporate Governance with the Balanced Scorecard The authors... View Details
- Profile
Mike Monagle
business and then moved into a strategic role managing company interests in Asia. As it became clearer that Mike wanted to build a business of his own, he recognized a need to expand his skills and “reflect on my future,” he says. “In the right program, I could View Details
- Mar 2012
- Article
Rethinking School
Economists have found that the higher a country's academic test scores, the faster its GDP grows. That puts the United States' perennially mediocre test scores in a particularly ominous light. Progress is... View Details
- 17 Feb 2016
- Research & Ideas
Man vs. Machine: Which Makes Better Hires?
Some companies have begun relying more on computer-administered tests than human interviewers to find the best applicants. New research by Harvard Business School Assistant Professor Danielle Li and colleagues suggests that in this case,... View Details
- March 2016 (Revised March 2022)
- Teaching Note
Evive Health and Workplace Influenza Vaccinations
By: John Beshears
Evive Health is a company that manages communication campaigns on behalf of health insurance plans and large employers. Using big data techniques and insights from behavioral economics, Evive deploys targeted and effective messages that improve individuals' health... View Details
Keywords: Vaccination; Influenza; Flu Shot; Preventive Care; Health Care; Behavioral Economics; Choice Architecture; Nudge; Experimental Design; Randomized Controlled Trial; RCT; Causal Inference; Health Care and Treatment; Insurance; Health; Consumer Behavior; Health Testing and Trials; Communication Strategy; Insurance Industry; Health Industry
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company... View Details
Keywords: Cash Burn; Cash Flow Analysis; Pharmaceutical Companies; Founder; Artificial Intelligence; AI; Entrepreneurship; Health Testing and Trials; Health Care and Treatment; Decision Making; Market Entry and Exit; AI and Machine Learning; Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)
- March 2016
- Case
Evive Health and Workplace Influenza Vaccinations
By: John Beshears
Evive Health is a company that manages communication campaigns on behalf of health insurance plans and large employers. Using big data techniques and insights from behavioral economics, Evive deploys targeted and effective messages that improve individuals' health... View Details
Keywords: Vaccination; Influenza; Flu Shot; Preventive Care; Health Care; Behavioral Economics; Choice Architecture; Nudge; Experimental Design; Randomized Controlled Trial; RCT; Causal Inference; Consumer Behavior; Health Care and Treatment; Health Testing and Trials; Communication Strategy; Health Industry
Beshears, John. "Evive Health and Workplace Influenza Vaccinations." Harvard Business School Case 916-044, March 2016.
- 07 Aug 2000
- Research & Ideas
Rocket Science Retailing
Retailers can significantly improve forecast accuracy simply by updating their predictions based on early sales data, tracking the accuracy of their forecasts, getting product testing right, and using a variety of forecasting approaches.... View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
October. However, when the drug testing panel includes a proportionate share of Black participants, doctors are much more willing to write a prescription. Black patients, in turn, were more likely to trust a medicine when clinical trials... View Details
- December 2023 (Revised March 2024)
- Case
Manufacturing Moderna's Future
By: Satish Tadikonda and William Marks
In 2019, Moderna faced long odds of survival having failed to develop a successful clinical program out of the vast platform technology they had built around mRNA. Nearly overnight, the company skyrocketed to success with a vaccine for COVID-19, leading to an extremely... View Details
Keywords: Health Pandemics; Health Testing and Trials; Technological Innovation; Product Development; Production; Science-Based Business; Biotechnology Industry
Tadikonda, Satish, and William Marks. "Manufacturing Moderna's Future." Harvard Business School Case 824-076, December 2023. (Revised March 2024.)
- Web
Tools | New Venture Competition
Starting a Social Enterprise Experts from Foley Hoag LLP address high level legal issues that New Venture Competition business plan entrants might have, and practical advice for starting a business. Legal Aspects of Starting a Social Enterprise, Powerpoint Deck... View Details
- Web
International Applicants | MBA
transcript. The School reserves the right to withdraw any offer of admission if there is a discrepancy between the uploaded unofficial translation and the official original language transcript and/or the official translation. English Language View Details
- January 2017
- Supplement
Terrapin Laboratory: Exercise
By: Joseph B. Fuller and Christopher Payton
In this exercise, we examine the capital requirements of Terrapin Laboratory as they contemplate entering into a new market segment. The company is faced with two potential financing options which have different effects on the ownership structure of the company.... View Details
- Profile
Lindsay Hyde
in a simulated climb of Mt. Everest,” she says. “It was a great way to start the year, to begin thinking about how we want to develop as leaders.” In FIELD 2, Lindsay and her team helped an Indian retailer, Nalli Silk Sarees, develop a new service for the home-goods... View Details